The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Mineralys Therapeutics, Inc.(NASDAQ:MLYS)


Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in...
Website: https://mineralystx.com
Founded: 2019
IPO Price: $16 (Feb 10, 2023)
CEO: Jon Congleton
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
Mineralys Therapeutics . Op Cashflow Per Share ttm
Mineralys Therapeutics . Free Cashflow Per Share ttm
Mineralys Therapeutics . Cash Per Share ttm
Mineralys Therapeutics . (GAAP) P/E ratio ttm
Mineralys Therapeutics . P/B ratio ttm
No extra charts and metrics for this ticker.